Cargando…
Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report
INTRODUCTION: sorafenib, a tyrosine-kinase inhibitor, is widely used in the treatment of advanced hepatocellular carcinoma. Drug-related toxicities are generally mild but sorafenib, as other similar agents, may induce elevation of systemic arterial blood pressure levels in relation to an interaction...
Autores principales: | Valsuani, Chiara, Siclari, Olimpia, Camerini, Andrea, Canale, Maria Laura, Rondini, Marianna, Donati, Sara, Puccinelli, Paolo, Tartarelli, Gianna, Puccetti, Cheti, Amoroso, Domenico |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803930/ https://www.ncbi.nlm.nih.gov/pubmed/20062650 http://dx.doi.org/10.1186/1757-1626-2-9133 |
Ejemplares similares
-
Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)
por: Camerini, Andrea, et al.
Publicado: (2015) -
Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer
por: Camerini, Andrea, et al.
Publicado: (2011) -
Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy
por: Canale, Maria Laura, et al.
Publicado: (2020) -
Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial
por: Camerini, Andrea, et al.
Publicado: (2022) -
Prevention of chemotherapy-induced left ventricular dysfunction
por: Bisceglia, Irma, et al.
Publicado: (2021)